Fidaxomicin Use in the Pediatric Population with Clostridioides difficile
Meredith B Oliver,1 Byron P Vaughn2 1M Health Fairview, Masonic Children's Hospital, Minneapolis, MN, USA; 2Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, MN, USACorrespondence: Byron P Vaughn, Department of Medicine, 1-205 Philips Wangensteen Bui...
Saved in:
Main Authors: | Oliver MB (Author), Vaughn BP (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2022-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison of fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients
by: A. Krishna Rao, et al.
Published: (2022) -
Real-world effectiveness of fidaxomicin in patients at high risk of Clostridioides difficile recurrence
by: Benjamin Colwell, et al.
Published: (2024) -
The Risk of <i>Clostridioides difficile</i> Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts
by: Ronald G. Hall, et al.
Published: (2022) -
Fidaxomicin for the Treatment of <i>Clostridioides difficile</i> Infection in Adult Patients: An Update on Results from Randomized Controlled Trials
by: Daniele Roberto Giacobbe, et al.
Published: (2022) -
Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of <i>Clostridioides difficile</i> Infection
by: Laura Whitney, et al.
Published: (2023)